email

Email:

info@biotech-pack.com

Free Quote
百泰派克蛋白质测序
百泰派克蛋白质组学服务
百泰派克生物制药分析服务
百泰派克代谢组学服务

Whole-process Immunopeptidomics Service: From Sample to Neoantigen Screening

Tumor immunotherapy has experienced a leap in development, from immune checkpoint inhibitors to personalized vaccines and TCR-T cell therapy. Precisely activating T cells to recognize tumors is regarded as an important direction for future treatments. Neoantigens, new peptide fragments produced by tumor-specific genetic mutations, are ideal targets for inducing tumor-specific immune responses due to their highly non-self nature. However, screening for neoantigens is far from easy. Methods such as predicting MHC-binding peptides using in vitro algorithms have certain throughput but still face bottlenecks like high false-positive rates and uncertain functionality. Especially in the context of personalized treatment, prediction models alone cannot satisfy clinical and research needs for the true presentation state of neoantigens. Against this backdrop, immunopeptidomics, a mass spectrometry technique that directly analyzes peptides presented by MHC complexes, is gradually becoming a key method for discovering neoantigens. Compared to predictions, immunopeptidomics offers a measured perspective, allowing researchers to directly identify real peptides presented by MHC molecules under physiological conditions, providing more biologically significant evidence for neoantigen validation and target development.

 

1. Technical Principles and Process Analysis of Immunopeptidomics

The core of immunopeptidomics is to enrich MHC molecules using immunoprecipitation techniques and identify the peptides bound to them through high-resolution mass spectrometry, thus reconstructing the true map of antigen presentation. The technical process includes the following key steps:

1. Sample Preparation

Supports various sample sources such as tumor tissue, cell lines, and PBMCs. The pretreatment process must preserve the integrity of antigen peptides to the greatest extent and avoid degradation.

 

2. MHC Immunoprecipitation (IP)

Using specific antibodies to enrich MHC-I or MHC-II complexes ensures the specificity of peptide sources and is key to the success of the entire process.

 

3. Peptide Release and Purification

Gentle acid treatment releases short peptides from MHC molecules, followed by purification using solid-phase extraction to remove impurities and nonspecific interference.

 

4. Mass Spectrometry Analysis (LC-MS/MS)

Using high-resolution mass spectrometry equipment (such as Orbitrap Exploris or timsTOF), precisely identify and quantify short peptides typically 8-15 amino acids in length.

 

5. Database Matching and Neoantigen Screening

Match mass spectrometry results with personalized peptide databases constructed based on patient mutation information (such as WES/RNA-seq) to identify peptides with potential mutation origins, i.e., potential neoantigens.

 

2. Technical Challenges and Key Optimization Points

Although immunopeptidomics has significant advantages, the technical barriers are relatively high, requiring precise control in the following aspects:

1. Enrichment Capability of Low-abundance Peptides

Neoantigens are often expressed at low abundance, making optimization of MHC antibody selection and IP conditions crucial.

 

2. Mass Spectrometry Sensitivity and Recognition Efficiency for Short Peptides

Compared to conventional proteomics, immunopeptidomics relies more on high-sensitivity equipment and precise mass spectrometry parameter settings.

 

3. High-confidence Peptide Identification Algorithms

Data processing requires combining multiple algorithms (such as NetMHCpan, MixMHCpred) and strict FDR control to ensure the accuracy of results.

 

3. Application Value: Bridging Data and Target

Immunopeptidomics technology is gradually becoming a core bridge connecting omics data and therapeutic targets, with application value reflected in multiple aspects:

  • Discovering targets for personalized tumor vaccines or T cell therapy
  • Evaluating tumor immunogenicity and antigen escape mechanisms
  • Studying antigen presentation profiles in viral infections or autoimmune diseases
  • Assisting in evaluating drug mechanisms or toxicity reactions

Especially in the field of precision medicine, the introduction of immunopeptidomics has transformed antigen validation from a passive prediction + validation mode to one based on real presentation from the start, improving research efficiency and clinical translation success rates.


As the trend of personalization in tumor immunotherapy becomes increasingly prominent, identifying truly presented neoantigens is becoming a new frontier in drug development and target research. Immunopeptidomics technology not only enhances the credibility of neoantigen screening but also provides researchers with more biologically significant discovery pathways. Biotech company Biotai will continue to empower the entire process of immunotherapy research with cutting-edge mass spectrometry technology, helping scientists grasp the true signals of immune recognition and advance the clinical implementation of precision medicine.

 

Biotai Biotech – Quality service provider for bioproduct characterization and multi-omics biomass spectrometry detection

 

Related Services:

Immunopeptidomics analysis and neoantigen discovery based on high-precision mass spectrometry

Submit Inquiry
Name *
Email Address *
Phone Number
Inquiry Project *
Project Description*

 

How to order?